Cannabis Stocks Land on Robinhood as Alabama Cuts the Ribbon

Cannabis Stocks Land on Robinhood as Alabama Cuts the Ribbon — The Week Normalization Got Real

For years, the American cannabis industry has operated like a business hiding in plain sight: legal in most states, banned by the federal government, and walled off from the ordinary machinery of capital and commerce. This week, two of those walls quietly came down at once. Plant-touching multistate operators began trading on Robinhood, the retail brokerage app that introduced a generation to investing, and Alabama became the fortieth state to put medical cannabis on a dispensary shelf. Neither event was a blockbuster on its own. Together, they marked the clearest sign yet that the post-rescheduling era is reshaping how the industry raises money and reaches customers.

The Robinhood development is the one operators have been waiting on. About a month after federal medical marijuana rescheduling took effect, stocks in plant-touching cannabis multistate operators began trading on the app, opening the sector to the millions of retail investors who use it. Green Thumb Industries appeared to be first to the punch — founder and CEO Ben Kovler announced the listing himself — with other MSOs following quickly. Curaleaf's founder confirmed that investors can now buy $CURLF on the platform, and the AdvisorShares Pure US Cannabis ETF, which trades under the ticker MSOS, is now available on Robinhood as well. For an industry whose equities have long been stranded on over-the-counter markets and thinly traded foreign exchanges, access to mainstream retail order flow is a structural change, not a cosmetic one.

Why does a brokerage listing matter so much? Because liquidity is destiny in capital markets. Cannabis companies have struggled to attract institutional money in part because their shares were hard to buy, hard to sell, and excluded from the platforms where most Americans hold their portfolios. Even modest improvements in accessibility can widen the buyer pool, tighten bid-ask spreads, and lower the cost of capital — the lifeblood of an industry that has spent years starved of affordable financing. It is worth keeping expectations measured: a Robinhood listing does not change the federal tax burden under Section 280E for products still outside the rescheduling order, nor does it solve cannabis banking. But it changes who can participate, and that is not nothing.

The fundamentals beneath the enthusiasm are mixed, which is exactly why the access story matters. The broader U.S. cannabis market is on track to approach roughly $47 billion in 2026, building on the approximately $33.8 billion in retail sales recorded in 2025. Yet margins remain under pressure. Wholesale flower pricing offers a window into the squeeze: the U.S. Cannabis Spot Index sat at $1,044 per pound in early June, a level that continues to test the economics of cultivators in saturated markets. Operators are leaning on scale and brand to survive. Green Thumb, for its part, reported first-quarter revenue of $300.2 million, up 7.4% year over year, with normalized EBITDA of $93.5 million — proof that disciplined MSOs can still grow profitably even in a grinding price environment.

The week's other marquee event unfolded in Montgomery, Alabama, where a five-year wait finally ended. The state's first licensed dispensary opened its doors, and patient advocate Amanda Taylor became the first legal purchaser at Callie's Apothecary, buying a water-soluble tincture and a peach-flavored gel cube. The opening made Alabama the fortieth U.S. state where medical cannabis is legally accessible, with three additional dispensary companies expected to open sites by summer. For operators eyeing new markets, Alabama is a reminder that whitespace still exists in the Southeast even as mature states slide toward oversupply.

State-level economics, however, continue to deliver hard lessons about tax design. In Michigan, the new 24% wholesale marijuana tax generated nearly $34 million through April 30 — far below the roughly $105 million officials had projected for a single quarter. The shortfall is a cautionary tale for any state tempted to treat cannabis as a bottomless revenue source: punitive tax rates can suppress legal volume and push consumers back toward untaxed channels, undercutting the very revenue lawmakers were chasing.

Up in Canada, the digital side of the business showed real momentum. E-commerce operator Herbal Dispatch reported that direct-to-consumer medical revenue rose 98% year over year to $761,375 in the first quarter, a jump driven largely by insured veterans — a segment that has become a reliable growth engine for Canadian operators. Aurora Cannabis underscored the same theme, highlighting its Strains for Heroes program, which donates 5% of net profits from those products to veteran-focused organizations, up to $200,000 annually.

Taken together, the week sketched an industry inching from the margins toward the mainstream — new investors arriving through Robinhood, a new state market opening, and reliable demand cohorts like veterans anchoring digital sales. The headwinds have not vanished; tax shortfalls, depressed wholesale prices, and an unfinished federal picture all remain. But for operators and investors who have spent a decade waiting for cannabis to be treated like a normal business, this was a week where normal finally felt a little closer.